Hanyou Pharmaceutical: FDA Accepts IND Application for HY3003 Injection

36Kr reports that Hanyou Pharmaceutical announced it recently received notification from the US FDA accepting its Investigational New Drug (IND) application for the HY3003 injection. The drug is a GLP-1R/GIPR/GCGR triple-target receptor agonist screened using AI peptide chip technology, intended for indications including weight loss and type 2 diabetes, formulated as a weekly subcutaneous injection. Preliminary clinical research indicates its weight-loss efficacy surpasses that of the already-marketed dual-target agonist tirzepatide. This IND acceptance marks a significant milestone in the internationalization of the company's innovative drug pipeline; if the FDA does not raise objections within 30 days, human clinical trials may commence.